Two major regulatory shifts landed in Latin America last week alongside a global GCP framework update and a fresh U.S. IND acceleration proposal, giving sponsors and CROs new operational levers to consider before their next protocol filing.
Brazil · Peru · ANVISA · INS · ICH · FDA · NAMSA · Veranex · Chagas · continuous-submission · decentralized-trials · FIH
bioaccess® | Global Trial Accelerators™ | Fast-Tracking First-in-Human Trials, Anywhere
Read the full newsletter online here.
Two major regulatory shifts landed in Latin America last week alongside a global GCP framework update and a fresh U.S. IND acceleration proposal, giving sponsors and CROs new operational levers to consider before their next protocol filing. This edition covers the developments most likely to affect clinical research planning through Q3 2026.
Take a closer look at the six clinical research signals below that sponsors, CROs, and site networks should factor into their next planning cycle.
On July 8, ANVISA's Diretoria Colegiada approved a new Instrução Normativa operationalizing the continuous submission mechanism established in RDC nº 945/2024. Sponsors can now submit documents composing the Dossiê do Produto sob Investigação — including stability data and analytical method validation — progressively as they are generated, rather than in a single bundle at DDCM submission. The rule also permits references to CADIFA and pharmacopeial monographs for active pharmaceutical ingredient documentation in specific situations. The change complements Lei 14.874/2024's parallel-review provisions, signaling Brazil's regulatory culture is converging with EMA-style rolling review conventions.
Why It Matters: Sponsors and CROs should redesign document-readiness sequencing to align with incremental submission windows and prepare API dossier alternatives leveraging CADIFA cross-references. Programs currently pending Brazilian authorization should confirm with regulatory counsel whether the IN's transitional provisions permit re-filing under continuous submission.
On July 8, Peru's Instituto Nacional de Salud published Resolución Directoral N.° 291-2026-INS/DI, rescinding POE-DIIS-002 (technical intake and assignment of clinical trial dossiers) and POE-DIIS-003 (technical review of trial authorization applications). Both procedures had structured how DIIS reviewers evaluated investigator qualifications, sponsor documentation, and protocol suitability for the past several years. Sponsors with active or pending INS submissions should confirm with local regulatory counsel which replacement procedure applies to their expediente, as legacy references in existing submission templates must be updated to avoid procedural rejection.
Bottom Line: Peru's clinical trial pathway is entering a transition window with no published replacement procedures. Sponsors evaluating Peru as an FIH or Phase 2 destination should model both accelerated and delayed scenarios in their country-selection matrices until the INS publishes the replacement framework, expected within thirty days per Peruvian administrative convention.
The International Council for Harmonisation adopted Annex 2 to the ICH E6(R3) GCP guideline on July 10, 2026. Annex 2 codifies GCP expectations for decentralized trial elements (home visits, remote patient interactions), pragmatic trial elements (integration with routine clinical care), and real-world data use in interventional studies, covering IRB communication, investigator oversight, sponsor governance, safety monitoring, informed consent, and digital-health-technology validation. ANVISA, COFEPRIS, and ANMAT are ICH Regulatory Members and are expected to implement Annex 2 within their normal transposition timelines.
What to Focus On: Companies running or planning hybrid-decentralized programs across LATAM sites should audit platform vendors' GCP certifications, refresh investigator training to reflect Annex 2 obligations, and review sponsor oversight documentation before the end of Q3 2026.
Through Resolução RE nº 2.631 published in the Diário Oficial da União on July 2, ANVISA approved pediatric use of Bayer's Lampit (nifurtimox) for Chagas disease in patients from 2.5 kg body weight through age 18. The decision expands treatment access for a disease that remains a public health priority across Brazil, Bolivia, Argentina, Paraguay, and other endemic Latin American countries. Pediatric Chagas programs have historically struggled with low commercial pull and complex enrollment logistics; a Brazil-approved comparator now exists for future Phase 2/3 or long-term extension protocols.
Why It Matters: Sponsors developing complementary Chagas therapies planning LATAM-inclusive Phase 2/3 programs now have a comparator benchmark cleared by ANVISA and should factor Lampit's labeled pediatric indication into study design and control-arm strategy. Program-level economics for LATAM-focused neglected-tropical-disease work continue to strengthen.
The U.S. FDA opened a public request for information on its proposed Expedited Investigational New Drug Pilot Program, with comments accepted through July 22, 2026. The initiative proposes a network of qualified research institutions, CROs, and regulatory advisors that would collaborate with sponsors to accelerate the path from drug discovery to first-in-human studies. The pilot is intended to identify structural bottlenecks in current IND workflows and pilot new coordination models across sponsor-CRO-institution triads.
Bottom Line: LATAM-based CROs with FIH execution capability and cross-border regulatory advisory experience should evaluate whether to submit an RFI response — for direct participation in any pilot network and to raise visibility with the sponsor community currently forming its position on the framework. Program-strategy leaders should consider how a U.S. Expedited IND pathway would sequence with LATAM FIH programs already positioned as time-and-cost advantaged.
Two U.S.-anchored CROs made notable moves during the week of July 4-10 signaling continued consolidation pressure in early-phase clinical research. NAMSA posted three new roles across five hubs, including a Senior Clinical Research Associate contractor position, an Associate Study Director in Northwood, Ohio, and multi-city laboratory-scientist postings across Irvine, Atlanta, St. Paul, Minneapolis, and Northwood. Veranex separately posted a Senior Clinical Study Manager role explicitly supporting first-in-human and early-feasibility-study execution, alongside a senior business development leader and expanded engineering and quality capacity. Both firms are systematically building integrated preclinical-clinical development platforms via distributed U.S. hubs.
What to Focus On: LATAM-focused CROs should sharpen positioning around country-level regulatory fluency, site relationships, and speed to first-patient-in — the competencies U.S. integrated platforms cannot easily replicate. Sponsors should evaluate NAMSA and Veranex on lifecycle-integrated development economics rather than headline pricing, and LATAM providers on their ability to compress the FIH-to-Phase-2 transition.
---
At bioaccess®, we help MedTech, Biopharma, and Radiopharma innovators accelerate first-in-human trials across Latin America — with the regulatory depth, site relationships, and operational execution that emerging markets demand. From INVIMA to ANVISA to COFEPRIS to ANMAT, our teams work inside the frameworks reshaping the region so sponsors don't have to. Explore our roadmap.
---
---
bioaccess® | Fast-Tracking First-in-Human Trials, Anywhere.
Follow bioaccess® on LinkedIn. | Subscribe to Global Trial Accelerators™.
← All Global Trial Accelerators editions · Contact bioaccess®